These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 18587731)

  • 1. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
    Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
    J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
    Glaspy JA; Charu V; Luo D; Moyo V; Kamin M; Wilhelm FE
    Cancer; 2009 Mar; 115(5):1121-31. PubMed ID: 19170225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
    Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
    Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M; Vetter A; Thyroff-Friesinger U;
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-every-2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients.
    Mircescu G; Gârneată L; Ciocâlteu A; Golea O; Gherman-Căprioară M; Capsa D; Mota E; Gusbeth-Tatomir P; Ghenu A; Bălută S; Constantinovici N; Covic AC
    Am J Kidney Dis; 2006 Sep; 48(3):445-55. PubMed ID: 16931218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
    Granetto C; Ricci S; Martoni A; Pezzella G; Testore F; Mattioli R; Lampignano M; Tacconi F; Porrozzi S; Gasparini G; Mantovani G;
    Oncol Rep; 2003; 10(5):1289-96. PubMed ID: 12883695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
    Spinowitz B; Coyne DW; Lok CE; Fraticelli M; Azer M; Dalal S; Villa G; Rosansky S; Adamis H; Beyer U;
    Am J Nephrol; 2008; 28(2):280-9. PubMed ID: 18004064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia.
    Grzeszczak W; Sulowicz W; Rutkowski B; de Vecchi AF; Scanziani R; Durand PY; Bajo A; Vargemezis V;
    Nephrol Dial Transplant; 2005 May; 20(5):936-44. PubMed ID: 15769814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
    Milutinović S; Plavljanić E; Trkulja V
    Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.